1 day Ago By Defense World Staff
Anebulo Pharmaceuticals, Inc. ( NASDAQ:ANEB – Get Free Report ) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 10,800 shares, a drop of 6.
9% from the October 15th total of 11,600 shares. Based on an average daily trading volume, of 8,500 shares, the short-interest ratio is currently 1.3 days.
Currently, 0.1% of the shares of the company are sold short. Analyst Upgrades and Downgrades Separately, Benchmark restated a “speculative buy” rating and issued a $8.
00 target price on shares of Anebulo Pharmaceuticals in a research note on Tuesday. View Our Latest Research Report on ANEB Anebulo Pharmaceuticals Price Performance Anebulo Pharmaceuticals ( NASDAQ:ANEB – Get Free Report ) last announced its quarterly earnings results on Wednesday, September 25th. The company reported ($0.
05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.08.
Analysts anticipate that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year. About Anebulo Pharmaceuticals ( Get Free Report ) Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.
The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Featured Articles Five stocks we like better than Anebulo Pharmaceuticals 3 Grocery Stocks That Are Proving They Are Still Essential Super Micro Computer Soars 28%: Is It Really Out of the Woods? Consumer Staples Stocks, Explained Traders Are Flocking Back to Oil: What’s Fueling the Optimism How to Invest in the FAANG Stocks 3 Hot Stock Trends to Ride Into 2025 Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
